Fundamental data on the pathologies amyloid and Tau in Alzheimer's disease: Which therapeutic perspectives?;Données fondamentales sur les pathologies amyloïde et Tau dans la maladie d'Alzheimer : quelles perspectives thérapeutiques ?

Annales Pharmaceutiques Francaises

Volumn 67, Issue 2, 2009, Pages 136-153

  Checler, F ^a,b   Buee L ^c  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b CNRS   (France)

^c JEAN PIERRE AUBERT RESEARCH CENTER   (France)

Author keywords

Alzheimer; Amyloid; Immunotherapy; Tau; Therapeutic

Indexed keywords

ALPHA TOCOPHEROL; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; ANTIOXIDANT; BETA SECRETASE; BETA SECRETASE INHIBITOR; CENTRAL NERVOUS SYSTEM AGENTS; CHOLINESTERASE INHIBITOR; CLIOQUINOL; DONEPEZIL; ESTRADIOL; FLAVONOID; FLURBIPROFEN; GALANTAMINE; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; HOMOTAURINE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; N METHYL DEXTRO ASPARTIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PF 4360365; PHOSPHOTRANSFERASE INHIBITOR; RIVASTIGMINE; SELEGILINE; TACRINE; TAU PROTEIN; UNINDEXED DRUG; VITAMIN;

ALZHEIMER DISEASE; ARTICLE; CATABOLISM; CLINICAL TRIAL; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOTHERAPY; MEDICAL RESEARCH; PROSPECTIVE STUDY; PROTEIN DETERMINATION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; UBIQUITINATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; CHOLINESTERASE INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; IMMUNOTHERAPY; NEUROPROTECTIVE AGENTS; TAU PROTEINS;

EID: 67049139964     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2009.01.002     Document Type: Article

References (117)

1. Bartus R.T., Dean R.L., Beer B., and Lippas A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 217 (1982) 408-414
2. Lleo A., Greenberg S., and Jh G. Current pharmacotherapy for Alzheimer's disease. Annu Rev Med 57 (2006) 513-533
3. Takeda A., Loveman E., Clegg A., Kirby J., Picot J., Payne E., et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int J Geriatr Psychiatry 21 (2006) 17-28
4. Fu A.-L., Zhang X.-M., and Sun M.-J. Antisense inhibition of acetylcholinesterase gene expression for treating cognition deficit in Alzheimer's disease model mice. Brain Res 1066 (2005) 10-15
5. Levi-Montalcini R. The nerve growth factor 35 years later. Science 237 (1987) 1154-1162
6. Fischer W., Wictorin K., Bjorklund A., Williams L., Varon S., and Gage F. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 329 (1987) 65-68
7. Tuszynski M.H.U.H.-S., Amaral D.G., and Gage F.H. Nerve growth factor infusion in primate brain reduces lesion-induced cholinergic neuronal degeneration. J Neurosci 10 (1990) 3604-3614
8. Tuszynski M.H., Thal L., Pay M., Salmon D.P.U.H.-S., et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer's disease. Nat Med 11 (2005) 551-555
9. Tariot P., Farlow M., Grossberg G., Graham S., Mcdonald S., and Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291 (2004) 317-324
10. Glenner G.G., and Wong C.W. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. BBRC 122 (1984) 1131-1135
11. Glenner G.G., and Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. BBRC 120 (1984) 885-890
12. Masters C.L., Simons G., Weinman N.A., Multhaup G., Mc Donald B.L., et al. Amyloid plaque core protein in Alzheimer's Disease and Down Syndrome. Proc Natl Acad Sci USA 82 (1985) 4245-4249
13. Goldgaber D., Lerman M.I., Mcbride O.W., Saffiotti U., and Gajdusek D.C. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 235 (1987) 880-887
14. Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325 (1987) 733-736
15. Tanzi R.E., Gusella J.F., Watkins P.C., Bruns G.A.P., St George-Hyslop P., et al. Amyloid b protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 235 (1987) 880-884
16. Tanzi R.E., St George-Hyslop P., and Gusella J.F. Molecular genetics of Alzheimer disease amyloid. J Biol Chem 266 (1991) 20579-20582
17. Mullan M., and Crawford F. Genetic and molecular advances in Alzheimer's disease. Trends Neurosci 16 (1993) 398-403
18. Schellenberg G.D. Genetic dissection of Alzheimer disease, a heterogeneous disorder. Proc Natl Acad Sci USA 92 (1995) 8552-8559
19. Levy-Lahad E., Wasco W., Poorkaj P., Romano D.M., Oshima J., et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269 (1995) 973-977
20. Rogaev E.I., Sherrington R., Rogaeva E.A., Levesque G., Ikeda M., et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376 (1995) 775-778
21. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375 (1995) 754-760
22. Alzheimer's disease collaborative group. The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Nat Genet 11 (1996) 219-222
23. Checler F. Processing of the b-amyloid precursor protein and its regulation in Alzheimer's disease. J Neurochem 65 (1995) 1431-1444
24. Burdick D., Kosmoski J., Knauer M.F., and Glabe C.G. Preferential adsorption, internalization and resistance to degradation of the major isoform of the Alzheimer's amyloid peptide, Ab1-42, in differentiated PC12. Brain Res 746 (1997) 275-284
25. Selkoe D.J. Alzheimer's disease: Genes, proteins and therapy. Physiol Rev 81 (2001) 741-766
26. Passer B., Pellegrini L., Russo C., Siegel R.M., Lenardio M.J., et al. Generation of an apoptotic intracellular peptide by g-secretase cleavage of Alzheimer's amyloid b protein precursor. J Alzheimers Dis 2 (2000) 289-301
27. Gu Y., Misonou H., Sato T., Dohmae N., Takio K., et al. Distinct intramembrane cleavages of the b-amyloid precursor protein family resembling g-secretase-like cleavage of Notch. J Biol Chem 276 (2001) 35235-35238
28. Sastre M., Steiner H., Fuchs K., Capell A., Multhaup G., et al. Presenilin dependent g-secretase processing of b-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO report 2 (2001) 835-841
29. Weidemann A., Eggert S., Reinhard F.B.M., Vogel M., Paliga K., et al. A novel e-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with the Notch processing. Biochemistry 41 (2002) 2825-2835
30. Cao X., and Südhof T.C. A transcriptively active complex of APP with Fe65 and histone acetyltransferase tip60. Science 293 (2001) 115-120
31. Baek S.H., Ohgi K.A., Rose D.W., Koo E.H., Glass C.K., et al. Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kB and b-amyloid precursor protein. Cell 110 (2002) 55-67
32. Pardossi-Piquard R., Petit A., Kawarai T., Sunyach C., Alves Da Costa C., et al. Presenilin-dependent transcriptional control of the A ß-degrading enzyme neprilysin by intracellular domains of ßAPP and APLP. Neuron 46 (2005) 541-554
33. Alves Da Costa C., Sunyach C., Pardossi-Piquard R., Sevalle J., Vincent B., et al. Presenilin-dependent g-secretase-mediated control of p53-associated cell death in Alzheimer's disease. J Neurosci 26 (2006) 6377-6385
34. Mattson M.P. Cellular actions of b-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 77 (1997) 1081-1132
35. Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., et al. Amyloid b-peptide is produced by cultured cells during normal metabolism. Nature 359 (1992) 322-325
36. Shoji M., Golde T.E., Ghiso J., Cheung T.T., Estus S., et al. Production of the Alzheimer amyloid b protein by normal proteolytic processing. Science 258 (1992) 126-129
37. Hussain I., Powell D., Howlett D.R., Tew D.G., Meek T.D., et al. Identification of a novel aspartic protease (Asp2) as b-secretase. Mol Cell Neurosci 14 (1999) 419-427
38. Sinha S., Anderson J.P., Barbour R., Basi G.S., and Caccavello R. Purification and cloning of amyloid precursor protein b-secretase from human brain. Nature 402 (1999) 537-540
39. Yan R., Bienkowski M.J., Shuck M.E., Miao H., Tory M.C., et al. Membrane-anchored aspartyl protease with Alzheimer's disease b-secretase activity. Nature 402 (1999) 533-537
40. Lin X., Koelsch G., Wu S., Downs D., Dashti A., et al. Human aspartyl protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci USA 97 (2000) 1456-1460
41. Cai H., Wang Y., Mccarthy D., Wen H., Borchelt D.R., et al. BACE1 is the major b-secretase for generation of Ab peptides by neurons. Nat Neurosci 4 (2001) 233-234
42. Luo Y., Bolon B., Kahn S., Bennett B.D., Babu-Khan S., et al. Mice deficient in BACE1, the Alzheimer's b-secretase, have normal phenotype and abolished b-amyloid generation. Nat Neurosci 4 (2001) 231-232
43. Roberds S.L., Anderson J., Basi G., Bienkowski M.J., Branstetter D.G., et al. BACE knockout mice are healthy despite lacking the primary b-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Gen 10 (2001) 1317-1324
44. Checler F. Presenilins: multifunctional proteins involved in Alzheimer's disease pathology. IUBMB Life 48 (1999) 33-39
45. Herreman A., Serneels L., Annaert W., Collen D., Schoonjans L., and De Strooper B. Total inactivation of ß-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol 2 (2000) 461-462
46. Zhang Z., Nadeau P., Song W., Donoviel D., Yuan M., et al. Presenilins are required for ß-secretase cleavage of ßAPP and transmembrane cleavage of Notch. Nat Cell Biol 2 (2000) 463-465
47. Goutte C., Hepler W., Mickey K., and Priess J. aph-2 encodes a novel extracellular protein required for GLP-1-mediated signaling. Development 127 (2000) 2481-2492
48. Yu G., Nishimura M., Arawaka S., Levitan D., Zhang L., et al. Nicastrin modulates presenilin-mediated notch/glp1 signal transduction and bAPP processing. Nature 407 (2000) 48-54
49. Francis R., Mcgrath G., Zhang J., Ruddy Da, Sym M., et al. Aph-1 and pen2 are required for notch pathway signaling, g-secretase cleavage of bAPP and presenilin protein accumulation. Dev Cell 3 (2002) 85-97
50. Lopez-Perez E., Zhang Y., Franck S.J., Creemers J., Seidah N., et al. Constitutive a-secretase cleavage of the b-amyloid precursor protein in the furin-deficient LoVo cell line: involvement of the prohormone convertase 7 (PC7) and the disintegrin metalloprotease ADAM10. J Neurochem 76 (2001) 1532-1539
51. Buxbaum J.D., Liu K.N., Luo Y., Slack J.L., Stocking K.L., et al. Evidence that tumor necrosis factor a converting enzyme is involved in regulated a-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 273 (1998) 27765-27767
52. Postina R., Schroeder A., Dewachter I., Bohl J., Schmitt U., et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer's disease mouse model. J Clin Invest 113 (2004) 1456-1464
53. Carson J.A., and Turner A.J. ß-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases. J Neurochem 81 (2002) 1-8
54. Eckman E.A., Watson M., Marlow L., Sambamurti K., and Eckman C.B. Alzheimer's disease b-amyloid peptide (Ab) is increased in mice deficient in endothelin-converting enzyme. J Biol Chem 278 (2003) 2081-2084
55. Willem M., Garratt A.N., Novak B., Citron M., Kaufmann S., et al. Control of peripheral nerve myelination by the beta-secretase BACE1. Science 314 (2006) 664-666
56. Singer O., Marr R.A., Rockenstein E., Crews L., Coufal N.G., et al. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 8 (2005) 1343-1349
57. Arbel M., Yacoby I., and Solomon B. Inhibition of amyloid precursor protein processing by (-secretase through site-directed antibodies. Proc Natl Acad Sci USA 102 (2005) 7718-7723
58. De Strooper B. Aph-1, Pen-2, and nicastrin with presenilin generate an active ß-secretase complex. Neuron 38 (2003) 9-12
59. Kopan R., and Goate A. A common enzyme connects Notch signaling and Alzheimer's disease. Genes Dev 14 (2000) 2799-2806
60. Szekely C.A., Thorne J.E., and Zandi P.P. Non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23 (2004) 159-169
61. Poirier J. Apolipoprotein E represents a potent gene-based therapeutic target for the treatment of sporadic Alzheimer's disease. Alzheimers Dement 4 (2008) S91-S97
62. Geerlings M., Launer L., De Jong F., Ruitenberg A., Stijnen T., et al. Endogenous estradiol and risk of dementia in women and men: the Rotterdam Study. Ann Neurol 53 (2003) 607-615
63. Price K.A., Crouch P.J., and White A.R. Therapeutic treatment of Alzheimer's disease using metal complexing agents. Recent Patents CNS Drug Discov 2 (2007) 180-187
64. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., et al. Immunization with amyloid-beta attenuates alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
65. Schenk D. Treatment of Alzheimer's disease: The beginning of a new era. Curr Alzheimer Res 3 (2006) 177
66. Bard F., Cannon C., Barbour R., Burke R.L., Games D., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6 (2000) 916-919
67. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., and Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98 (2001) 8850-8855
68. Lombardo J.A., Stern E.A., Mclellan M.E., Kajdasz S.T., Hickey G.A., et al. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci 23 (2003) 10879-10883
69. Das P., Howard V., Loosbrock N., Dickson D., Murphy M.P., and Golde T.E. Amyloid-beta immunization effectively reduces amyloid deposition in Fcrgamma-/- Knock-out Mice. J Neurosci 23 (2003) 8532-8538
70. Solomon B. Generation of anti-beta-amyloid antibodies via phage display technology towards Alzheimer's disease vaccination. Vaccine 23 (2005) 2327-2330
71. Demattos R.B., Bales K.R., Cummins D.J., Paul S.M., and Holtzman D.M. Brain to plasma amyloid-beta efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's Disease. Science 295 (2002) 2264-2267
72. Nikolic W.V., Bai Y., Obregon D., Hou H., Mori T., et al. Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. Proc Natl Acad Sci USA 104 (2007) 2507-2512 Epub 2007 Jan 30
73. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: The end of the beginning. Nat Rev Neurosci 3 (2002) 824-828
74. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., et al. Subacute meningoencephalitis in a subset of patients with AD after abeta42 immunization. Neurology 61 (2003) 46-54
75. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., et al. Clinical effects of abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 (2005) 1553-1562
76. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372 (2008) 216-223
77. Dodel R., Hampel H., Depboylu C., Lin S., Gao F., et al. Human antibodies against amyloid beta peptide: A potential treatment for Alzheimer's disease. Ann Neurol 52 (2002) 253-256
78. Istrin G., Bosis E., and Solomon B. Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. J Neurosci Res 84 (2006) 434-443
79. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, et al. 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. Sous presse.
80. Wisniewski T., and Konietzko U. Amyloid-beta immunisation for Alzheimer's disease. Lancet Neurol. 7 (2008) 805-811
81. Brion J.P. Mise en évidence immunologique de la protéine Tau au niveau des lésions de dégénérescence neurofibrillaire de la maladie d'Alzheimer. Arch Biol (Brux) 95 (1985) 229-235
82. Buée L., Bussiere T., Buée-Scherrer V., Delacourte A., and Hof P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33 (2000) 95-130
83. Lee V.M., Goedert M., and Trojanowski J.Q. Neurodegenerative tauopathies. Annu Rev Neurosci 24 (2001) 1121-1159
84. Sergeant N., Delacourte A., and Buée L. Tau Protein as a differential biomarker of tauopathies. Biochim Biophys Acta 1739 (2005) 179-197
85. Schraen-Maschke S., Sergeant N., Dhaenens C.M., Bombois S., Deramecourt V., Caillet-Boudin M.L., et al. Tau as biomarker for neurodegenerative diseases. Biomarkers Med 2 (2008) 363-384
86. Delacourte A., Sergeant N., Champain D., Wattez A., Maurage C.A., et al. Nonoverlapping but Synergetic Tau and APP pathologies in sporadic Alzheimer's disease. Neurology 59 (2002) 398-407
87. Cleveland D.W., Hwo S.Y., and Kirschner M.W. Purification of Tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J Mol Biol 116 (1977) 207-225
88. Goedert M., Spillantini M.G., Jakes R., Rutherford D., and Crowther R.A. Multiple isoforms of human microtubule-associated protein Tau: Sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3 (1989) 519-526
89. Goedert M., Spillantini M.G., Potier M.C., Ulrich J., and Crowther R.A. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein Tau containing four tandem repeats: Differential expression of Tau protein Mrnas in human brain. EMBO J 8 (1989) 393-399
90. Iqbal K., and Grundke-Iqbal I. Pharmacological approaches of neurofibrillary degeneration. Curr Alzheimer Res 2 (2005) 335-341
91. Galas M.C., Dourlen P., Begard S., Ando K., Blum D., et al. The peptidylprolyl Cis/Trans-isomerase Pin1 modulates stress-induced dephosphorylation of Tau in neurons: Implication in a pathological mechanism related to Alzheimer disease. J Biol Chem 281 (2006) 19296-19304
92. Hamdane M., Dourlen P., Bretteville A., Sambo A.V., Ferreira S., et al. Pin1 allows for differential tau dephosphorylation in neuronal cells. Mol Cell Neurosci 32 (2006) 155-160
93. Lefebvre T., Caillet-Boudin M.L., Buée L., Delacourte A., and Michalski J.C. O-GlcNac glycosylation and neurological disorders. Adv Exp Med Biol 535 (2003) 189-202
94. Petrucelli L., and Dawson T.M. Mechanism of neurodegenerative disease: Role of the ubiquitin proteasome system. Ann Med 36 (2004) 315-320
95. Mori H., Kondo J., and Ihara Y. Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science 235 (1987) 1641-1644
96. Petrucelli L., Dickson D., Kehoe K., Taylor J., Snyder H., et al. Chip and Hsp70 regulate Tau ubiquitination, degradation and aggregation. Hum Mol Genet 13 (2004) 703-714
97. Rissman R.A., Poon W.W., Blurton-Jones M., Oddo S., Torp R., et al. Caspase-cleavage of Tau is an early event in Alzheimer disease tangle pathology. J Clin Invest 114 (2004) 121-130
98. Braak H., Alafuzoff I., Arzberger T., Kretzschmar H., and Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol (Berl) 112 (2006) 389-404
99. Gotz J., Chen F., Van Dorpe J., and Nitsch R.M. Formation of neurofibrillary tangles in P301l Tau transgenic mice induced by Abeta 42 fibrils. Science 293 (2001) 1491-1495
100. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant Tau and APP. Science 293 (2001) 1487-1491
101. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., et al. Reducing endogenous Tau ameliorates amyloid (-induced deficits in an Alzheimer's disease mouse model. Science 316 (2007) 10.1126/science.1141736
102. Schindowski K., Bretteville A., Leroy K., Begard S., Brion J.P., et al. Alzheimer's disease-like Tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated Tau transgenic mouse without any motor deficits. Am J Pathol 169 (2006) 599-616
103. Lewis J., Mcgowan E., Rockwood J., Melrose H., Nacharaju P., et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) Tau protein. Nat Genet 25 (2000) 402-405
104. Santacruz K., Lewis J., Spires T., Paulson J., Kotilinek L., et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309 (2005) 476-481
105. Gotz J., Chen F., Barmettler R., and Nitsch R.M. Tau filament formation in transgenic mice expressing P301l Tau. J Biol Chem 276 (2001) 529-534
106. Allen B., Ingram E., Takao M., Smith M.J., Jakes R., et al. Abundant Tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301s Tau protein. J Neurosci 22 (2002) 9340-9351
107. Churcher I. Tau therapeutic strategies for the treatment of Alzheimer's disease. Curr Top Med Chem 6 (2006) 579-595
108. Mandelkow E.M., Stamer K., Vogel R., Thies E., and Mandelkow E. Clogging of axons by Tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 24 (2003) 1079-1085
109. Zhang B., Maiti A., Shively S., Lakhani F., Mcdonald-Jones G., et al. Microtubule-binding drugs offset Tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA 102 (2005) 227-231
110. Noble W., Planel E., Zehr C., Olm V., Meyerson J., et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 102 (2005) 6990-6995
111. Le Corre S., Klafki H.W., Plesnila N., Hubinger G., Obermeier A., et al. An Inhibitor of Tau hyperphosphorylation prevents severe motor impairments in Tau transgenic mice. Proc Natl Acad Sci USA 103 (2006) 9673-9678
112. Tsai L.H., Lee M.S., and Cruz J. Cdk5, a therapeutic target for Alzheimer's disease?. Biochim Biophys Acta 1697 (2004) 137-142
113. Smet C., Duckert J.F., Wieruszeski J.M., Landrieu I., Buée L., et al. Control of protein-protein interactions: Structure-based discovery of low molecular weight inhibitors of the interactions between Pin1 Ww domain and phosphopeptides. J Med Chem 48 (2005) 4815-4823
114. Smet C., Sambo A.V., Wieruszeski J.M., Leroy A., Landrieu I., et al. The Peptidyl prolyl Cis/Trans-isomerase Pin1 recognizes the phospho-Thr212-Pro213 site on Tau. Biochemistry 43 (2004) 2032-2040
115. Pickhardt M., Gazova Z., Von Bergen M., Khlistunova I., Wang Y., et al. Anthraquinones inhibit Tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J Biol Chem 280 (2005) 3628-3635
116. Lippens G., Sillen A., Smet C., Wieruszeski J.M., Leroy A., et al. Studying the natively unfolded neuronal Tau protein by solution NMR spectroscopy. Protein Pept Lett 13 (2006) 235-246
117. Necula M., Chirita C.N., and Kuret J. Cyanine dye N744 Inhibits Tau fibrillization by blocking filament extension: Implications for the treatment of tauopathic neurodegenerative diseases. Biochemistry 44 (2005) 10227-10237